These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

613 related items for PubMed ID: 27221806

  • 1. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N.
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
    Sabale U, Ekman M, Granström O, Bergenheim K, McEwan P.
    Prim Care Diabetes; 2015 Feb; 9(1):39-47. PubMed ID: 24840612
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
    Cai X, Shi L, Yang W, Gu S, Chen Y, Nie L, Ji L.
    J Med Econ; 2019 Apr; 22(4):336-343. PubMed ID: 30663458
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G, Tzanetakos C, Ioannidis I, Tsapas A, Kourlaba G, Papageorgiou G, Maniadakis N.
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [Abstract] [Full Text] [Related]

  • 8. Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
    Elsisi GH, Anwar MM, Khattab M, Elebrashy I, Wafa A, Elhadad H, Awad M, Carapinha JL.
    J Med Econ; 2020 Aug; 23(8):908-914. PubMed ID: 32364032
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
    Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, Liu S, Shi L.
    Curr Med Res Opin; 2017 Feb; 33(2):359-369. PubMed ID: 27817216
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes.
    Pawaskar M, Bilir SP, Kowal S, Gonzalez C, Rajpathak S, Davies G.
    Am J Manag Care; 2019 May; 25(5):231-238. PubMed ID: 31120717
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Chien CL, Chen YC, Malone DC, Peng YL, Ko Y.
    Curr Med Res Opin; 2020 Oct; 36(10):1619-1626. PubMed ID: 32851879
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
    Gourzoulidis G, Tzanetakos C, Ioannidis I, Tsimihodimos V, Diogo V, Karpouzos G, Papageorgiou G, Kourlaba G.
    Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.